Quantcast
Last updated on April 18, 2014 at 14:49 EDT

Vasomedical Retains KCSA Strategic Communications as Corporate Communications Counsel

October 31, 2012

WESTBURY, N.Y., Oct. 31, 2012 /PRNewswire/ — Vasomedical, Inc. (“Vasomedical”) (OTCQB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology as well as in the domestic sale of diagnostic imaging products, announced today that it has retained KCSA Strategic Communications (KCSA), a leading New York-based communications firm, to direct the Company’s investor relations and public relations programs.

(Logo: http://photos.prnewswire.com/prnh/20120517/NY09396LOGO)

KCSA will deploy an integrated investor and public relations campaign designed to increase awareness of Vasomedical, its proprietary technology and its business model among the investment community, targeting the healthcare and medical device sectors, in addition to outreach to business and trade publications.

Since KCSA’s inception more than 40 years ago, the firm has developed a strong reputation for its work representing domestic and international companies across all industries, including medical devices, healthcare services and biotechnology. Todd Fromer and Lewis Goldberg, Managing Partners of KCSA, will lead the communications team and provide strategic counsel on financial and media communication matters.

“We understand the importance of a proactive communications program to effectively reach the investment community in general, our shareholders in particular, as well as the media. As we continue to grow our business, we look forward to working closely with KCSA to effectively communicate our growth strategy and operational progress through all of the appropriate channels. As our superior healthcare solutions move into global markets, we see increased demand from healthcare professionals, distributors and consultants, which will significantly further our business. The engagement of a leading IR/PR firm such as KCSA will greatly assist us in achieving our mission,” said Dr. Jun Ma, President and Chief Executive Officer of Vasomedical, Inc.

“Vasomedical is executing on a clear strategy to expand its operations, increase sales and build shareholder value,” said Todd Fromer, Managing Partner of KCSA Strategic Communications. “The Company’s management team and Board of Directors have expressed a strong commitment to increasing awareness among its core constituents. Based on our successful track record of working with dozens of micro-cap healthcare companies, we believe KCSA is the right firm to help tell this compelling story. We look forward to providing our complete range of services to support Vasomedical’s integrated communications initiatives in the healthcare industry.”

About Vasomedical
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company operates through three wholly owned subsidiaries. Vasomedical Solutions manages and coordinates the design, manufacture and sales of EECP(®) Therapy systems, its core product, as well as other medical equipment operations; Vasomedical Global operates the Company’s China-based subsidiaries; and Vaso Diagnostics, d/b/a VasoHealthcare, is the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products. Additional information is available on the Company’s website at www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

About KCSA Strategic Communications
KCSA is a fully-integrated communications agency specializing in public relations, investor relations and marketing with expertise in financial and professional services, technology, healthcare, media, energy and public services companies. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm’s clients are its best references. For more information, please visit www.kcsa.com.

Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
Phone: 212-896-1215 / 212-896-1250
Email: tfromer@kcsa.com / grussell@kcsa.com

Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
Phone: 212-896-1216 / 212-896-1220
Email: lgoldberg@kcsa.com / swolf@kcsa.com

SOURCE KCSA Strategic Communications


Source: PR Newswire